Washington Report

Jan 01, 2014
Pharmaceutical Executive
Pricing and personalized medicine are key themes shaping drug development and marketing
Dec 01, 2013
Pharmaceutical Executive
The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.
Nov 01, 2013
Pharmaceutical Executive
High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise.
Oct 01, 2013
Pharmaceutical Executive
Tension mounts over biosimilars, co-pay coupons, trade, and testing.
Sep 01, 2013
Pharmaceutical Executive
Rising costs will mean a drop in anticipated NDAs next year, reflecting an ever-longer and more costly drug-development process that is squeezing pharma investment in R&D.
Aug 01, 2013
Pharmaceutical Executive
Rate cuts and fraud concerns create problems for Part D plans and Part B providers.
Jul 01, 2013
Pharmaceutical Executive
FDA wants pharma leaders to do more to ensure drug quality at home and abroad. Our Washington correspondent Jill Wechsler reports.
Jun 01, 2013
Pharmaceutical Executive
The backlash against high prices for new medicines will impact research, patent exclusivity, and drug benefits.
May 01, 2013
Pharmaceutical Executive
Legal battles and regulatory missteps undermine access to low-cost generics, at home and abroad, writes Jill Wechsler.
Apr 01, 2013
Pharmaceutical Executive
There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices.
native1_300x100
lorem ipsum